These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31220592)

  • 1. NOEL and NOAEL: A retrospective analysis of mention in a sample of recently conducted safety pharmacology studies.
    Baird TJ; Caruso MJ; Gauvin DV; Dalton JA
    J Pharmacol Toxicol Methods; 2019; 99():106597. PubMed ID: 31220592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a role for the no observed adverse effect level in safety pharmacology?
    Mow T; Andersen NK; Dragsted N; Lassen AB; Laursen M; Bass AS; Valentin JP; Markgraf C; Authier S; Baird TJ; Bhatt S; Traebert M; Leishman DJ; Jones D; Curtis MJ
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106917. PubMed ID: 32866658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A New Way in Deciding NOAEL Based on the Findings from GLP-Toxicity Test.
    Park YC; Cho MH
    Toxicol Res; 2011 Sep; 27(3):133-5. PubMed ID: 24278562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.
    Contrera JF; Matthews EJ; Kruhlak NL; Benz RD
    Regul Toxicol Pharmacol; 2004 Dec; 40(3):185-206. PubMed ID: 15546675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scientific and Regulatory Policy Committee: Recommended ("Best") Practices for Determining, Communicating, and Using Adverse Effect Data from Nonclinical Studies.
    Kerlin R; Bolon B; Burkhardt J; Francke S; Greaves P; Meador V; Popp J
    Toxicol Pathol; 2016 Feb; 44(2):147-62. PubMed ID: 26704930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twenty years of safety pharmacology model validation and the wider implications of this to drug discovery.
    Pugsley MK; Bekele B; Griessel H; de Korte T; Authier S; Grobler AF; Markgraf CG; Curtis MJ
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106912. PubMed ID: 32798702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical Considerations in Determining Adversity and the No-Observed-Adverse-Effect-Level (NOAEL) in Nonclinical Safety Studies: Challenges, Perspectives and Case Studies.
    Kale VP; Bebenek I; Ghantous H; Kapeghian J; Singh BP; Thomas LJ
    Int J Toxicol; 2022; 41(2):143-162. PubMed ID: 35230174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recognition of adverse and nonadverse effects in toxicity studies.
    Lewis RW; Billington R; Debryune E; Gamer A; Lang B; Carpanini F
    Toxicol Pathol; 2002; 30(1):66-74. PubMed ID: 11890477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicologic Pathology Forum: Opinion on Approaches for Reporting Toxic and Adverse Dose Levels in Nonclinical Toxicology Studies Supporting the Development of Anticancer Pharmaceuticals.
    Hukkanen RR; Moriyama T; Patrick DJ; Werner J
    Toxicol Pathol; 2023 Jan; 51(1-2):81-86. PubMed ID: 36695335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cis-1,1,1,4,4,4-hexafluoro-2-butene (HFO-1336mzz-Z) (2018).
    Toxicol Ind Health; 2019 Mar; 35(3):180-188. PubMed ID: 30760179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Safety Profiles of Blood Cancer Drugs Approved in Japan.
    Kubota S; Saito K; Ono S; Kodama Y
    Ther Innov Regul Sci; 2016 Mar; 50(2):228-235. PubMed ID: 30227012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonclinical & clinical interface - extrapolation of nonclinical data to support Phase I clinical studies.
    Baldrick P; Reichl A
    Regul Toxicol Pharmacol; 2021 Apr; 121():104869. PubMed ID: 33482290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s).
    Dorato MA; Engelhardt JA
    Regul Toxicol Pharmacol; 2005 Aug; 42(3):265-74. PubMed ID: 15979222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety pharmacology investigations in toxicology studies: an industry survey.
    Authier S; Vargas HM; Curtis MJ; Holbrook M; Pugsley MK
    J Pharmacol Toxicol Methods; 2013; 68(1):44-51. PubMed ID: 23685201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical warfare agents: estimating oral reference doses.
    Opresko DM; Young RA; Faust RA; Talmage SS; Watson AP; Ross RH; Davidson KA; King J
    Rev Environ Contam Toxicol; 1998; 156():1-183. PubMed ID: 9597943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing "Adversity" of Pathology Findings in Nonclinical Toxicity Studies: Results from the 4th ESTP International Expert Workshop.
    Palazzi X; Burkhardt JE; Caplain H; Dellarco V; Fant P; Foster JR; Francke S; Germann P; Gröters S; Harada T; Harleman J; Inui K; Kaufmann W; Lenz B; Nagai H; Pohlmeyer-Esch G; Schulte A; Skydsgaard M; Tomlinson L; Wood CE; Yoshida M
    Toxicol Pathol; 2016 Aug; 44(6):810-24. PubMed ID: 27102650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies.
    Andrade EL; Bento AF; Cavalli J; Oliveira SK; Schwanke RC; Siqueira JM; Freitas CS; Marcon R; Calixto JB
    Braz J Med Biol Res; 2016 Dec; 49(12):e5646. PubMed ID: 27982281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A nonclinical safety assessment of MnTE-2-PyP, a manganese porphyrin.
    Gad SC; Sullivan DW; Crapo JD; Spainhour CB
    Int J Toxicol; 2013 Jul; 32(4):274-87. PubMed ID: 23704100
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.